{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:16:00Z","timestamp":1790381760581,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.beha.2007.10.002","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T16:33:54Z","timestamp":1208450034000},"page":"665-680","source":"Crossref","is-referenced-by-count":38,"title":["Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation"],"prefix":"10.1016","volume":"20","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.10.002_bib1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","article-title":"Proteasome inhibitor bortezomib for the treatment of multiple myeloma","volume":"20","author":"Cavo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.leu.2403905","article-title":"Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside","volume":"19","author":"Bruno","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.leu.2403728","article-title":"Five decades of therapy for multiple myeloma: a paradigm for therapeutic models","volume":"19","author":"Kyle","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management","author":"Rajkumar","year":"2005","journal-title":"Hematology. American Society of Hematology. Education Program"},{"key":"10.1016\/j.beha.2007.10.002_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1,027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.002_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM198302103080604","article-title":"Long-term survival in multiple myeloma","volume":"308","author":"Kyle","year":"1983","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2007.10.002_bib8","first-page":"418a","article-title":"Single versus double transplant in myeloma: A randomized trial of the \u2018Inter Groupe Francais du Myelome\u2019 (IFM)","volume":"90","author":"Attal","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib10","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.002_bib12","first-page":"56","article-title":"Prognostic factors in multiple myeloma","volume":"2","author":"Kyle","year":"1995","journal-title":"Stem Cells"},{"key":"10.1016\/j.beha.2007.10.002_bib13","first-page":"65","article-title":"Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients","volume":"79","author":"Rapoport","year":"1990","journal-title":"South African Medical Journal"},{"key":"10.1016\/j.beha.2007.10.002_bib14","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.002_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0025-6196(12)61797-2","article-title":"Prognosis in myeloma","volume":"69","author":"Greipp","year":"1994","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.002_bib17","first-page":"84","author":"Greipp","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib18","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2013an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib19","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830200311","article-title":"Immunofluorescent plasma cell labeling indices (Li) using a monoclonal antibody (Bu-1)","volume":"20","author":"Greipp","year":"1985","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.beha.2007.10.002_bib21","first-page":"12","article-title":"Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487 (Meeting abstract)","author":"Greipp","year":"1993","journal-title":"Proceedings of the Annual Meeting of the American Society of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V72.1.219.219","article-title":"Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma","volume":"72","author":"Greipp","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib23","first-page":"348","article-title":"Clinical application of cell kinetics to patients with monoclonal gammopathy and multiple myeloma","volume":"23","author":"Greipp","year":"1990","journal-title":"Cell and Tissue Kinetics"},{"key":"10.1016\/j.beha.2007.10.002_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1989.7.1.119","article-title":"Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis","volume":"7","author":"Boccadoro","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.1991.9.3.444","article-title":"Multiple myeloma: VMCP\/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients","volume":"9","author":"Boccadoro","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V59.1.43.43","article-title":"Ploidy and proliferative characteristics in monoclonal gammopathies","volume":"59","author":"Latreille","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.1994.12.1.115","article-title":"MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents","volume":"12","author":"Cornelissen","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000206109","article-title":"Analysis of human myeloma cell population kinetics","volume":"75","author":"Montecucco","year":"1986","journal-title":"Acta Haematologica (Basel)"},{"key":"10.1016\/j.beha.2007.10.002_bib29","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1997.15.7.2659","article-title":"Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants","volume":"15","author":"Tricot","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2007.10.002_bib30","first-page":"527a","article-title":"Abnormal cytogenetics predict for poor survival after peripheral stem cell transplantation in relapsed multiple myeloma","volume":"90","author":"Rajkumar","year":"1997","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2007.10.002_bib31","first-page":"527a","article-title":"Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT)","volume":"90","author":"Simpson","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"Gutierrez","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib33","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.leu.2403857","article-title":"Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma","volume":"19","author":"Ross","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.1998.00657.x","article-title":"Prognostic value of cytogenetics in multiple myeloma","volume":"101","author":"Seong","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib35","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2003.03948.x","article-title":"Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II","volume":"120","author":"Shaughnessy","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib38","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib40","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1046\/j.1365-2141.2000.02488.x","article-title":"Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13","volume":"111","author":"Avet-Louseau","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib41","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2007.10.002_bib42","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2404330","article-title":"The role of cytogenetics in myeloma","volume":"20","author":"Zhan","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.leu.2404450","article-title":"An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma","volume":"21","author":"Dispenzieri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib45","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib46","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","article-title":"Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation","volume":"103","author":"Kroger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib47","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.leu.2404333","article-title":"The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"20","author":"Bensinger","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.leu.2404459","article-title":"Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion","volume":"21","author":"Sagaster","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib50","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2007.10.002_bib53","first-page":"390a","article-title":"Hypodiploid myeloma revisited: response to therapy and survival in Eastern Cooperative Oncology Group Study E9486","volume":"88","author":"Trendle","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib54","first-page":"3854","article-title":"Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2007.10.002_bib55","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","article-title":"Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Drach","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x","article-title":"Multiple myeloma-almost all patients are cytogenetically abnormal","volume":"94","author":"Zandecki","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib57","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib58","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib59","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib61","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a P53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4065\/82.3.323","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.002_bib63","first-page":"141","article-title":"Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia","volume":"4","author":"Anonymous","year":"1973","journal-title":"Cancer Chemotherapy Reports. Part 3"},{"key":"10.1016\/j.beha.2007.10.002_bib64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C","article-title":"Combination chemotherapy for multiple myeloma","volume":"30","author":"Alexanian","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.002_bib65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","article-title":"Myeloma protein kinetics following chemotherapy","volume":"60","author":"McLaughlin","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428199609052427","article-title":"Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma","volume":"20","author":"Oken","year":"1996","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.10.002_bib67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib68","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib69","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.leu.2404574","article-title":"Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin","volume":"21","author":"Durie","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib70","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/clinchem\/48.4.655","article-title":"Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma","volume":"48","author":"Abraham","year":"2002","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.beha.2007.10.002_bib71","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.beha.2007.10.002_bib72","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib74","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib75","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","article-title":"Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.002_bib77","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"The International Myeloma Working Group","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.002_bib78","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.10.002_bib79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib80","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2005.06.147","article-title":"Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system","volume":"23","author":"Baldini","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.002_bib81","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.10.002_bib82","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis of monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.002_bib83","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib84","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.002_bib85","series-title":"Cecil textbook of medicine","first-page":"1184","article-title":"Plasma cell disorders","author":"Kyle","year":"2004"},{"key":"10.1016\/j.beha.2007.10.002_bib86","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/asheducation-2005.1.360","article-title":"POEMS syndrome","author":"Dispenzieri","year":"2005","journal-title":"Hematology. American Society of Hematology. Education Program"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:10:17Z","timestamp":1631095817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1521692607000771"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.10.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}